Our platform combines pathogen-reduced human plasma with novel polysaccharides. That means we take human plasma, conduct steps to enhance its safety, and add molecules (chitosan) which deliver antimicrobial qualities and/or improved consistency. We do this with the goal of enhancing the efficacy of the growth factors (for healing) and clotting proteins the plasma contains. We are evaluating the use of these products to promote the healing of epithelial (surface cell) disorders such as dry eye disease, diabetic ulcers, ophthalmic burns, and chronic wounds.

ECI has robust patents protecting the formulation that combines serum-like plasma with a novel antimicrobial molecule (chitosan) to create products ranging from liquid eye drops to healing gels, ointments, contact lenses, contoured bandages and wound dressings.

Our novel products synergistically combine the immediate tissue-repairing benefits of plasma or plasma derivatives with the sustained action of chitosan, to provide both instant relief and long-lasting therapeutic action.